{"id":"kdf1901","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Without publicly available information on KDF1901's molecular target or mechanism, the precise biological pathway cannot be determined. The drug remains in clinical development, and detailed mechanistic data may be proprietary or under regulatory review.","oneSentence":"KDF1901 is an investigational therapeutic agent in phase 3 development by Kyungdong Pharmaceutical, but its specific mechanism of action has not been publicly disclosed.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:17:47.169Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07116863","phase":"PHASE3","title":"A Multicenter, Randomized, Double-Blind Phase 3 Trial of KDF1901 in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Kyungdong Pharmaceutical Co., Ltd.","startDate":"2022-06-21","conditions":"Essential Hypertension","enrollment":286}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"KDF1901","genericName":"KDF1901","companyName":"Kyungdong Pharmaceutical Co., Ltd.","companyId":"kyungdong-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}